Results & Financial lifeHealthcare - Pharma - Biotech
Inside Information / Other news releases
05/11/2026 18:00
AMFImmediate publication
Malakoff, November 5, 2026, 6:00 pm CET - THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a platform for the non-invasive treatment of varicose veins using High-Intensity Focused Ultrasound (HIFU), today announces that the U.S. Food and Drug…
THERACLION OBTAINS FDA AUTHORIZATION FOR
SONOVEIN®, OPENING A NEW ERA IN NON-INVASIVE
VEIN CARE IN THE UNITED STATES
- Sonovein® becomes the first non-invasive HIFU platform to receive U.S. marketing authorization for the treatment of superficial venous reflux in Great Saphenous Vein (GSV) segments through the FDA’s De Novo pathway.
- Access to the world’s largest varicose vein treatment market opens a transformative growth opportunity for Theraclion.
- Following years of technological development and clinical validation, Theraclion enters a new phase focused on commercial deployment and adoption.
- With months of preparation completed and its U.S. subsidiary established, Theraclion is ready to execute the commercial launch in the U.S.
Malakoff, November 5, 2026, 6:00 pm CET - THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a platform for the non-invasive treatment of varicose veins using High-Intensity Focused Ultrasound (HIFU), today announces that the U.S. Food and Drug Administration (FDA) granted De Novo marketing authorization for Sonovein® on November 4, 2026. In the United States, Sonovein® is intended for the coagulation of blood vessels in patients with superficial vein reflux in the Great Saphenous Vein (GSV) segments. Superficial venous reflux, most often involving the GSV, is the main cause of varicose veins, a condition affecting approximately one third of adults.
This decision marks a major advance for U.S. patients, bringing access to a novel technology that treats targeted veins entirely from outside the body, without an incision or an intravascular catheter. For Theraclion, the authorization represents a historic turning point. It brings years of research, technological development and clinical validation to fruition, while opening the U.S. market and a new phase of commercial growth.
A historic milestone and a new chapter
“This authorization marks the culmination of years of clinical and regulatory work and opens a defining new chapter for Theraclion. Sonovein® enables entirely non-invasive vein treatment, without incisions or catheters. We are proud to bring this fundamental advance to U.S. patients and physicians. I thank our teams, clinical investigators, partners and shareholders, whose dedication and belief in our vision helped make this achievement possible. We also thank the FDA for its constructive engagement throughout the review process,” said Martin Deterre, Chief Executive Officer of Theraclion. “This milestone also marks the starting point for U.S. commercialization. Our priority is to establish successful treatment centers, build sustained adoption and deliver growth. After months of preparation, with our launch plan refined and our U.S. subsidiary, Sonovein Inc., established, we are ready to hit the ground running.”